S V Mandrov

Regional Clinical Hospital, Krasnoyarsk, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does S V Mandrov research?

S V Mandrov studies the use of Revelise, a medication for treating ischemic stroke, to see how effective it is in actual clinical settings. Specifically, they investigate how this treatment can help older patients and those with other health problems recover from strokes. By examining large groups of patients and their outcomes over time, Mandrov aims to provide insights into improving care and reducing disabilities that arise from strokes.

Key findings

  • In the International PRIMA Study involving 2,202 patients, 49.9% had good outcomes at discharge after receiving Revelise.
  • After 90 days, the percentage of patients with good outcomes increased to 66.4%.
  • The findings demonstrate that Revelise effectively reduces disabilities related to strokes, especially among older patients.

Frequently asked questions

Does Dr. Mandrov study stroke treatments?
Yes, Dr. Mandrov focuses on treatments for ischemic stroke, particularly the use of Revelise (alteplase).
What outcomes does Dr. Mandrov look at in his research?
Dr. Mandrov assesses the effectiveness of Revelise in reducing stroke-related disabilities and improving recovery outcomes for patients.
Is Dr. Mandrov's work relevant to older stroke patients?
Yes, much of Dr. Mandrov's research includes older patients, highlighting the safety and effectiveness of thrombolytic therapy in that population.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.